Intermittent AMPK priming potentiates senolytic clearance of senescent cells and rescues age‑related muscle hypertrophy

Hypothesis

Pre‑conditioning aged mice with intermittent AMPK activation (metformin pulses) before senolytic Dasatinib + Quercetin (D+Q) treatment enhances autophagic flux in senescent cells, making them more susceptible to senolytic‑induced apoptosis and reducing SASP secretion, thereby improving muscle hypertrophy without exacerbating immune‑mediated off‑target effects.

Mechanistic Rationale

Senescent cells exhibit defective autophagy that sustains their pro‑inflammatory SASP [[https://www.gethealthspan.com/research/article/ampk-mtor-cycling]]. AMPK activation phosphorylates ULK1, initiating autophagosome formation and restoring flux [[https://benbikman.com/ampk-and-mtor-the-metabolic-master-switches-of-aging/]]. Restored autophagy can lower SASP by degrading damaged mitochondria and inhibiting NF‑κB signaling, a key driver of SASP [[https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/]]. When autophagy is re‑engaged, senescent cells become primed for apoptosis because autophagic degradation of anti‑apoptotic BCL‑2 family proteins (e.g., MCL‑1) lowers the threshold for BCL‑2 inhibition by Dasatinib [[https://doi.org/10.1038/s41591-018-0092-9]]. Thus, intermittent AMPK activation creates a synthetic lethal interaction with D+Q, increasing senescent cell clearance efficiency while limiting the dose and frequency of senolytics needed.

Experimental Design

Animals: 24‑month‑old C57BL/6 mice (n=10 per group). Groups:

1. Vehicle control (saline + PBS).
2. Intermittent metformin alone (250 mg/kg i.p., 3 days on/4 days off for 2 weeks).
3. D+Q alone (Dasatinib 5 mg/kg + Quercetin 50 mg/kg, weekly ×3).
4. Metformin pre‑conditioning → D+Q (same metformin schedule for 2 weeks, then D+Q as in group 3). Readouts (performed 7 days after final D+Q dose):

• Senescent cell burden in gastrocnemius via aptamer‑based surface marker staining (e.g., uPAR aptamer) [[https://www.sciencedaily.com/releases/2025/12/251213032625.htm]] and flow cytometry.
• Autophagic flux (LC3‑II/I ratio, p62 levels) in isolated senescent cells.
• SASP cytokine panel (IL‑6, IL‑1β, MMP‑3) in serum and muscle homogenate.
• Muscle fiber cross‑sectional area and grip strength.
• Immune profiling (CD8⁺ T cell activation, NK cell infiltration) to assess off‑target immune activation.
• Survival monitoring over 6 months.

Predicted Outcomes

• Group 4 will show ≥50 % greater reduction in senescent cell frequency compared with D+Q alone (group 3), as measured by aptamer‑positive cells.
• Autophagic markers will be restored in senescent cells from group 4, correlating with decreased SASP levels.
• Muscle hypertrophy (fiber size ↑20 %) and grip strength improvement will be significantly higher in group 4 vs. groups 2 and 3, without increased CD8⁺ T cell activation or cytokine storm.
• Median survival extension in group 4 will exceed that of D+Q alone by ~15 % (approaching the 36 % increase seen with senolytics in prior work [[https://doi.org/10.1038/s41591-018-0092-9]]).

Potential Pitfalls and Alternatives

If intermittent metformin fails to augment autophagy in senescent cells, the hypothesis is falsified; we would then test direct AMPK activators (e.g., AICAR) or ULK1 agonists. Conversely, if enhanced clearance leads to heightened immune activation, the therapeutic window would be deemed narrow, prompting dose‑reduction studies. The design includes built‑in controls to disentangle metformin‑induced systemic effects from senescent‑cell‑specific autophagy restoration.

This framework directly links metabolic cycling to senolytic efficacy, offering a testable, falsifiable strategy to optimize combination regimens for age‑related tissue dysfunction.